Published in Medical Verdicts and Law Weekly, July 26th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Cytogen Corporation.
Report 1: Cytogen Corporation (NASDAQ: CYTO) reported updated data from a Phase 1 dose escalation study evaluating QUADRAMET(R) (samarium Sm-153 lexidronam injection) in combination with bortezomib (Velcade(R), Millennium Pharmaceuticals, Inc.) in patients with relapsed multiple myeloma. Data from 33 patients were presented today in a poster titled, "Phase 1 Trial of Bortezomib (Vel) and Samarium (Sam) in Multiple Myeloma," by James Berenson, M.D., Medical & Scientific...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly